Baricitinib is a small-molecule Janus kinase (JAK) inhibitor that selectively suppresses intracellular cell signaling against JAK1 and JAK2, but has weak activity against JAK3.[7] It was developed to treat patients with refractory RA who do not respond to conventional DMARDs. This evidence concerns the gene JAK3 and rheumatoid arthritis.